Abstract |
We developed an immunocompromised murine model of influenza virus infection and demonstrated comparable efficacy of oral oseltamivir and A-322278 (both given at dosages of 10 mg/kg/day) in reducing viral replication, decreasing weight loss, and prolonging survival. Once the treatment was discontinued, severe combined immunodeficient (SCID) mice had progressive viral replication and clinical decline. Drug-resistant variants were detected in 4 (29%) of 14 and 2 (13%) of 15 mice (both BALB/c and SCID) treated with oseltamivir or A-322278, respectively; no resistant variants were detected in placebo-treated mice. Amino acid substitutions in the hemagglutinin receptor-binding site at aa 137 or 225 were detected in cloned resistant isolates. A substitution in the neuraminidase (NA) active site (Arg292Lys) was detected in the cloned virus recovered from an oseltamivir-treated mouse. This model would be useful for elucidation of the molecular mechanisms of resistance to NA inhibitors and for testing of anti- influenza therapy options that might prevent the emergence of resistant variants.
|
Authors | Michael G Ison, Vasiliy P Mishin, Thomas J Braciale, Frederick G Hayden, Larisa V Gubareva |
Journal | The Journal of infectious diseases
(J Infect Dis)
Vol. 193
Issue 6
Pg. 765-72
(Mar 15 2006)
ISSN: 0022-1899 [Print] United States |
PMID | 16479509
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- A-322278
- Acetamides
- Pyrrolidines
- Oseltamivir
- Neuraminidase
|
Topics |
- Acetamides
(pharmacology, therapeutic use)
- Amino Acid Substitution
- Animals
- Disease Models, Animal
- Drug Resistance, Viral
- Immunocompetence
(immunology)
- Immunocompromised Host
(immunology)
- Influenza A virus
(drug effects, enzymology, genetics, pathogenicity)
- Mice
- Mice, Inbred BALB C
- Mice, SCID
- Neuraminidase
(antagonists & inhibitors, metabolism)
- Orthomyxoviridae Infections
(drug therapy)
- Oseltamivir
- Pyrrolidines
(pharmacology, therapeutic use)
|